INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3 | +50.0% | 154 | 0.0% | 0.00% | +50.0% |
Q2 2023 | $2 | 0.0% | 154 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $2 | 0.0% | 154 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $2 | -99.9% | 154 | 0.0% | 0.00% | -33.3% |
Q3 2022 | $2,000 | 0.0% | 154 | 0.0% | 0.00% | +50.0% |
Q2 2022 | $2,000 | -33.3% | 154 | 0.0% | 0.00% | -33.3% |
Q1 2022 | $3,000 | 0.0% | 154 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $3,000 | +50.0% | 154 | 0.0% | 0.00% | +50.0% |
Q3 2021 | $2,000 | -33.3% | 154 | 0.0% | 0.00% | -33.3% |
Q2 2021 | $3,000 | -25.0% | 154 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $4,000 | 0.0% | 154 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $4,000 | -33.3% | 154 | 0.0% | 0.00% | -50.0% |
Q3 2020 | $6,000 | -14.3% | 154 | 0.0% | 0.01% | 0.0% |
Q2 2020 | $7,000 | -30.0% | 154 | 0.0% | 0.01% | -40.0% |
Q1 2020 | $10,000 | -47.4% | 154 | 0.0% | 0.01% | -33.3% |
Q4 2019 | $19,000 | +90.0% | 154 | 0.0% | 0.02% | +87.5% |
Q3 2019 | $10,000 | -16.7% | 154 | 0.0% | 0.01% | -11.1% |
Q2 2019 | $12,000 | -29.4% | 154 | 0.0% | 0.01% | -35.7% |
Q1 2019 | $17,000 | +6.2% | 154 | 0.0% | 0.01% | 0.0% |
Q4 2018 | $16,000 | -15.8% | 154 | 0.0% | 0.01% | 0.0% |
Q3 2018 | $19,000 | – | 154 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |